Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOFIVA GENOMICS CoROCO:6615 -0.74%68 ROC (Joel Greenblatt) % is 54.48% as of Mar. 2026, which is 47% above its 10-year median of 37.16. GuruFocus rates ROCO:6615 with a GF Score™ of 68/100 and a GF Value™ of NT$31.62 (Fairly Valued). The stock has 3 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, SOFIVA GENOMICS Co ranks better than 61.43% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. SOFIVA GENOMICS Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 54.48%.
The historical rank and industry rank for SOFIVA GENOMICS Co's ROC (Joel Greenblatt) % or its related term are showing as below:
ROCO:6615'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.68 Med: 37.16 Max: 66.97
Current: 9.33
During the past 13 years, SOFIVA GENOMICS Co's highest ROC (Joel Greenblatt) % was 66.97%. The lowest was -5.68%. And the median was 37.16%.
ROCO:6615's ROC (Joel Greenblatt) % is ranked better than 61.43% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.15
vs ROCO:6615: 9.33
SOFIVA GENOMICS Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
SOFIVA GENOMICS Co (ROCO:6615) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
SOFIVA GENOMICS Co ROC (Joel Greenblatt) % Related Terms
SOFIVA GENOMICS Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for SOFIVA GENOMICS Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6615 vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's ROC (Joel Greenblatt) % falls into.
SOFIVA GENOMICS Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 54.48% mean?
SOFIVA GENOMICS Co (ROCO:6615) has a ROC (Joel Greenblatt) % of 54.48% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on SOFIVA GENOMICS Co and its competitors. This is 47% above median its historical median of 37.16. According to the industry distribution chart, SOFIVA GENOMICS Co ranks #81 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 38.6%.
Is SOFIVA GENOMICS Co's ROC (Joel Greenblatt) % too high?
SOFIVA GENOMICS Co's current ROC (Joel Greenblatt) % of 54.48% is 47% above median its 10-year median of 37.16. Based on the distribution chart, SOFIVA GENOMICS Co ranks #81 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SOFIVA GENOMICS Co ranks #81 out of 210 companies for ROC (Joel Greenblatt) %. This puts SOFIVA GENOMICS Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current ROC (Joel Greenblatt) % is 54.48%, which is 47% above median its own 10-year median of 37.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.62, compared to a current price of NT$33.75 — trading 6.7% above its estimated fair value. The current ROC (Joel Greenblatt) % is 54.48%, which is 47% above median its 10-year median of 37.16. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current ROC (Joel Greenblatt) % is 54.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$33.75 is trading 6.7% above its estimated GF Value™ of NT$31.62.
GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.
Key valuation signals for ROCO:6615:
ROC (Joel Greenblatt) %: 54.48% (47% above median its 10-year median of 37.16)
GF Value™: NT$31.62 vs. price of NT$33.75 (6.7% above fair value)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
